These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 7993908

  • 1. Kinetic mechanism for the interaction of Hirulog with thrombin.
    Parry MA, Maraganore JM, Stone SR.
    Biochemistry; 1994 Dec 13; 33(49):14807-14. PubMed ID: 7993908
    [Abstract] [Full Text] [Related]

  • 2. Hirulog-1 and -B2 thrombin specificity.
    Witting JI, Bourdon P, Maraganore JM, Fenton JW.
    Biochem J; 1992 Oct 15; 287 ( Pt 2)(Pt 2):663-4. PubMed ID: 1445227
    [No Abstract] [Full Text] [Related]

  • 3. Thrombin-specific inhibition by and slow cleavage of hirulog-1.
    Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW.
    Biochem J; 1992 May 01; 283 ( Pt 3)(Pt 3):737-43. PubMed ID: 1290488
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.
    Ofosu FA, Fenton JW, Maraganore J, Blajchman MA, Yang X, Smith L, Anvari N, Buchanan MR, Hirsh J.
    Biochem J; 1992 May 01; 283 ( Pt 3)(Pt 3):893-7. PubMed ID: 1590777
    [Abstract] [Full Text] [Related]

  • 5. Intrinsic fluorescence changes and rapid kinetics of the reaction of thrombin with hirudin.
    Jackman MP, Parry MA, Hofsteenge J, Stone SR.
    J Biol Chem; 1992 Aug 05; 267(22):15375-83. PubMed ID: 1639783
    [Abstract] [Full Text] [Related]

  • 6. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.
    Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW.
    Biochemistry; 1990 Jul 31; 29(30):7095-101. PubMed ID: 2223763
    [Abstract] [Full Text] [Related]

  • 7. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.
    Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A, Westbrook M, Maraganore JM.
    J Mol Biol; 1991 Oct 20; 221(4):1379-93. PubMed ID: 1942057
    [Abstract] [Full Text] [Related]

  • 8. Use of fragments of hirudin to investigate thrombin-hirudin interaction.
    Dennis S, Wallace A, Hofsteenge J, Stone SR.
    Eur J Biochem; 1990 Feb 22; 188(1):61-6. PubMed ID: 2180697
    [Abstract] [Full Text] [Related]

  • 9. Structure-function and refolding studies of the thrombin-specific inhibitor hirudin.
    Johnson PH, Sze P, Winant RC, Hudson D, Underhill P, Lazar JB, Olsen C, Almquist R.
    Haemostasis; 1991 Feb 22; 21 Suppl 1():41-8. PubMed ID: 1894196
    [Abstract] [Full Text] [Related]

  • 10. Proteolytic formation of either of the two prothrombin activation intermediates results in formation of a hirugen-binding site.
    Liu LW, Ye J, Johnson AE, Esmon CT.
    J Biol Chem; 1991 Dec 15; 266(35):23633-6. PubMed ID: 1748641
    [Abstract] [Full Text] [Related]

  • 11. Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors.
    Qiu X, Padmanabhan KP, Carperos VE, Tulinsky A, Kline T, Maraganore JM, Fenton JW.
    Biochemistry; 1992 Dec 01; 31(47):11689-97. PubMed ID: 1445905
    [Abstract] [Full Text] [Related]

  • 12. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
    Callas DD, Hoppensteadt D, Fareed J.
    Semin Thromb Hemost; 1995 Dec 01; 21(2):177-83. PubMed ID: 7660140
    [Abstract] [Full Text] [Related]

  • 13. Structure-function relationships of hirulog peptide interactions with thrombin.
    Bourdon P, Jablonski JA, Chao BH, Maraganore JM.
    FEBS Lett; 1991 Dec 09; 294(3):163-6. PubMed ID: 1756854
    [Abstract] [Full Text] [Related]

  • 14. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage.
    Kline T, Hammond C, Bourdon P, Maraganore JM.
    Biochem Biophys Res Commun; 1991 Jun 28; 177(3):1049-55. PubMed ID: 2059196
    [Abstract] [Full Text] [Related]

  • 15. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
    Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J.
    Thromb Haemost; 1993 Feb 01; 69(2):157-63. PubMed ID: 8456428
    [Abstract] [Full Text] [Related]

  • 16. The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alter its specificity.
    Ye J, Liu LW, Esmon CT, Johnson AE.
    J Biol Chem; 1992 Jun 05; 267(16):11023-8. PubMed ID: 1317850
    [Abstract] [Full Text] [Related]

  • 17. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
    Rubens FD, Weitz JI, Brash JL, Kinlough-Rathbone RL.
    Thromb Haemost; 1993 Feb 01; 69(2):130-4. PubMed ID: 8456425
    [Abstract] [Full Text] [Related]

  • 18. Platelet glycoprotein Ib alpha binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin.
    Li CQ, Vindigni A, Sadler JE, Wardell MR.
    J Biol Chem; 2001 Mar 02; 276(9):6161-8. PubMed ID: 11024046
    [Abstract] [Full Text] [Related]

  • 19. Rational design of hirulog-type inhibitors of thrombin.
    Egner U, Hoyer GA, Schleuning WD.
    J Comput Aided Mol Des; 1994 Oct 02; 8(5):479-90. PubMed ID: 7876896
    [Abstract] [Full Text] [Related]

  • 20. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation.
    Prasa D, Svendsen L, Stürzebecher J.
    Thromb Haemost; 1997 Mar 02; 77(3):498-503. PubMed ID: 9066001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.